Merck shareholder tries to scuttle the Idenix deal

Merck (MRK -0.3%) shareholder Ronald Burns files suit (Burns vs Idenix Pharmaceuticals) attempting to block its $3.9B acquisition of Idenix (IDIX +1.4%) stating that the price undervalues IDIX. He cites IDIX's intrinsic value and a flawed process that prevents competing bids.

The deal includes a no-solicitation clause, grants MRK the right to match any superior offer and stipulates a $115.6M termination fee. Mr. Burns alleges that these clauses virtually assure Merck gets the deal.

From other sites
Comments (2)
    , contributor
    Comments (18) | Send Message
    This suit is a very small nuisance by a bit player.
    16 Jun 2014, 08:56 PM Reply Like
  • MichaelJ8
    , contributor
    Comments (883) | Send Message
    but hes right, the deal is poor, IDIX could have gotten more, should have gotten at least 2x-3x more than what they got.
    17 Jun 2014, 12:14 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs